We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Cancer and Oncology
-
1. Endometrial cancer: integrating molecular insights into personalized care
- Dr. Gemma Eminowicz
-
4. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
-
5. Mode of action of T cells engineered with CAR or TCR for cancer treatment
- Prof. Sebastian Kobold
-
6. Immunotherapy: insights from advanced disease
- Dr. Sara M. Tolaney
-
7. Recent advances in the field of non-coding RNAs in cancer
- Prof. George Calin
- Dr. Maitri Shah
-
8. How tumor-microenvironment interactions drive or inhibit metastasis
- Prof. Isaac P. Witz
-
9. A novel cancer therapy to stimulate oncogenic ERK signalling
- Prof. Reiko Sugiura
-
10. MRD-driven multiple myeloma treatment: next step forward
- Prof. Ola Landgren
-
11. Germinal centre lymphomas: advances in diagnostic and therapeutic intervention
- Dr. Koorosh Korfi
- Prof. Jude Fitzgibbon
-
12. Immunotherapy in lung cancer
- Dr. Mark M. Awad
-
13. Preservation of fertility in cancer patients: the impact of chemotherapy
- Prof. Kutluk H. Oktay
-
15. Solution proposed to a 2000 year old problem in oncology
- Dr. Michael Retsky
- Clinical Practice
-
16. Comprehensive sickle cell care in the era of gene therapy
- Prof. Sophie Lanzkron
-
17. Stillbirth: diagnosis, investigation and aftercare
- Prof. Alexander E. P. Heazell
-
18. Analyzing the medical relevance of skin care trends
- Prof. Zoe Draelos
-
19. Genetic counseling: preconception, prenatal, perinatal
- Prof. Aubrey Milunsky
-
20. The past, present & future of ANA testing: history and challenges of ANA
- Prof. Marvin J. Fritzler
-
21. The past, present & future of ANA testing: changing bandwidth and future of ANA
- Prof. Marvin J. Fritzler
-
23. Mitochondrial diseases: an update
- Dr. Ayesha Saleem
-
24. Hemophilia A
- Dr. Snejana Krassova
-
27. Recent advances in diagnosis and interventions in ophthalmology
- Dr. Rebecca Kaye
- Prof. Andrew Lotery
- Gastroenterology
-
28. Building implantable human liver tissue from pluripotent stem cells
- Prof. David C. Hay
-
29. Microbiome therapies to treat gastrointestinal diseases
- Dr. Patricia Bloom
-
30. Drug-induced liver injury: importance, epidemiology, and mechanisms of DILI
- Prof. James H. Lewis
-
31. Drug-induced liver injury: risk factors and drug development in DILI
- Prof. James H. Lewis
-
32. Drug-induced liver injury: HDS, diagnosing, treating and preventing DILI
- Prof. James H. Lewis
-
33. An update on the multiple faces of celiac disease
- Prof. Aaron Lerner
- Immunology
-
34. Next-generation RNA vaccines
- Dr. Anna Blakney
-
35. Harnessing the immune system for cancer therapy
- Dr. Raghav Sundar
-
36. Rac-enhanced CAR immunotherapy: RaceCAR
- Prof. Denise Montell
-
37. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 1
- Prof. Kevin Harrington
-
38. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 2
- Prof. Kevin Harrington
-
39. Drug allergy: new knowledge
- Prof. Mariana C. Castells
-
40. Biologics as a treatment strategy in food allergy
- Prof. Sayantani B. Sindher
-
41. B cells at the crossroads of autoimmune diseases
- Dr. Xiang Lin
-
42. Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
-
43. Mathematical modeling in immunology
- Prof. Ruy M. Ribeiro
-
44. Therapeutic antibody development
- Prof. Dr. Katja Hanack
-
45. Understanding treatment coverage in mass drug administrations
- Dr. Margaret Baker
-
46. The thymus and T cell development: a primer
- Prof. Georg Holländer
- Infectious Diseases
-
48. HCV resistance
- Prof. John Dillon
-
49. The Global Virus Network: collaboration to address pandemic and regional threats
- Prof. Sten H. Vermund
-
50. New concepts in the management of CAP: a focus on severe illness - treatment and therapies
- Prof. Michael S. Niederman
-
51. New concepts in the management of CAP: a focus on severe illness - MRSA and MDR pathogens
- Prof. Michael S. Niederman
-
52. CRISPR-based suppression drives for vector control
- Prof. Andrea Crisanti
-
53. HIV cure: harnessing innate and adaptive strategies
- Prof. Luis Montaner
- Cardiovascular, Metabolism & Nutrition
-
54. Cow’s milk allergy: the future
- Dr. Carina Venter
-
55. Cow's milk allergy: management
- Dr. Carina Venter
-
56. Moving from GWAS hits to functional variants
- Prof. Steve Humphries
-
57. X-linked hypophosphataemia: genetics, diagnosis and management
- Prof. Thomas O. Carpenter
-
58. What is new in type 1 diabetes?
- Prof. Åke Lernmark
-
59. Current concepts for the management of patients with osteoporosis
- Dr. Michael Lewiecki
-
60. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
61. Peptide YY (PYY) in obesity and diabetes
- Dr. Nigel Irwin
- Microbiology
-
62. Vaccines and the fight against antimicrobial resistance 1
- Dr. Annaliesa S. Anderson
-
63. Vaccines and the fight against antimicrobial resistance 2
- Dr. Annaliesa S. Anderson
-
64. Vaccines as a weapon against antibiotic resistance
- Dr. Pumtiwitt McCarthy
-
65. PathoLive: pathogen detection while sequencing
- Dr. Simon Tausch
-
67. Successes and failures with vaccines
- Prof. Stanley Plotkin
-
68. Immunology, the microbiome and future perspectives
- Prof. Sheena Cruickshank
-
69. Impact of the HPV vaccine programme – a changing landscape
- Dr. Kevin Pollock
- Neurology and Neuroscience
-
71. Huxley’s science fiction: ion channels in pain, pain resilience, and beyond
- Prof. Stephen Waxman
-
72. Advances in the diagnosis and treatment of tardive dyskinesia
- Prof. Emeritus Stanley N. Caroff
-
73. Cellular therapies for neurological Injuries: bioreactors, potency, and coagulation
- Prof. Charles S. Cox, Jr.
-
74. Cardiovascular involvement in Parkinson’s disease
- Dr. David S. Goldstein
-
75. Molecular brain imaging (PET) in diseases with dementia
- Prof. Karl Herholz
-
76. Current thinking in pain medicine and some thoughts on back pain
- Dr. Nick Hacking
-
77. Bioelectronic medicine: immunomodulation by vagus nerve stimulation
- Prof. Paul Peter Tak
-
78. Developments & future directions in the management of chronic pain
- Prof. Simon Haroutounian
-
79. Deep Brain Stimulation (DBS) neuromodulation for Schizophrenia
- Prof. Judith Gault
-
80. Parkinson’s at 200 years: an update on Parkinson’s research in 2017
- Prof. Patrick A. Lewis
-
81. Alzheimer's disease: where are we up to?
- Prof. John Hardy
- Pharmaceutical Sciences
-
82. Bone marrow mesenchymal cells 1
- Prof. Arnold I. Caplan
-
83. Bone marrow mesenchymal cells 2
- Prof. Arnold I. Caplan
-
84. Peptide-drug conjugates as therapeutic modality in drug development 1
- Dr. Syed Faheem Askari Rizvi
-
85. Peptide-drug conjugates as therapeutic modality in drug development 2
- Dr. Syed Faheem Askari Rizvi
-
86. Pharmacokinetics, -dynamics and dosing considerations in children
- Prof. Dr. Karel Allegaert
-
87. Why in vitro permeation test – and not in vivo?
- Prof. Howard Maibach
-
88. The future of plasma-derived medicinal products (PDMP)
- Dr. Daniele Focosi
-
89. RNA therapeutics: clinical applications and methods of delivery
- Prof. John P. Cooke
-
90. Recent advances in the development of gene delivery technologies
- Dr. Takis Athanasopoulos
-
91. Preclinical translation of mesenchymal stem cell therapies
- Dr. Peter Childs
-
92. Modulating gene expression to treat diseases
- Dr. Navneet Matharu
-
93. Accelerating drug discovery with machine learning and AI
- Dr. Olexandr Isayev
-
94. Emerging big data in medicinal chemistry: promiscuity analysis as an example
- Prof. Dr. Jürgen Bajorath
- Dr. Ye Hu
-
95. Binding kinetics in drug discovery
- Dr. Rumin Zhang
-
96. Modeling of antibody-drug conjugate pharmacokinetics
- Dr. Dhaval K. Shah
-
97. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
98. Current challenges in the design of antibody-drug conjugates
- Prof. L. Nathan Tumey
-
99. Inorganic nanostructured interfaces for therapeutic delivery
- Prof. Tejal Desai
-
100. Latest development in therapy-related autophagy research
- Dr. Vignir Helgason
- Respiratory Diseases
-
101. Diagnosis of tuberculosis and drug resistant tuberculosis 1
- Dr. Daniela Cirillo
-
102. Diagnosis of tuberculosis and drug resistant tuberculosis 2
- Dr. Daniela Cirillo
-
103. Respiratory syncytial virus vaccination
- Prof. Peter Openshaw
-
104. Advances in gene therapy for respiratory diseases 1
- Prof. John F. Engelhardt
-
105. Advances in gene therapy for respiratory diseases 2
- Prof. John F. Engelhardt
-
106. Asthma
- Prof. William Busse
- Dr. Amanda McIntyre
-
107. New drugs for asthma
- Prof. Peter Barnes
-
108. CompEx asthma: a novel composite exacerbation endpoint
- Dr. Carla A. Da Silva
-
109. Updates in chronic obstructive pulmonary disease (COPD)
- Dr. Omar S. Usmani
- Archived Lectures *These may not cover the latest advances in the field
-
111. AI and big data in drug discovery
- Mr. Ed Addison
Printable Handouts
Navigable Slide Index
- Introduction
- Disclosure information
- Mesenchyme pronunciation
- Mesenchymal Stem Cells (1)
- Mesenchymal stem cells are not stem cells
- Lineages and stem cells
- Lineages
- My lineage, 1967
- Chick embryo limb bud
- Extracting mesenchymal cells from chick limb buds
- Limb mesenchymal cell differentiation
- Limb regeneration
- Committed progenitor cells
- Mesenchymal stem cells (2)
- In vitro MSCs derived from human bone marrow
- MSCs and tissue regeneration
- Adult bone marrow
- Osiris therapeutics
- The mesengenic process: 1988 hypothesis
- The mesengenic process: updated
- Mesenchymal stem cells (3)
- MSCs can be derived from multiple tissue sources
- Complex blood vessels
- Pericytes
- All MSCs are from pericytes!
- In vivo identity of pre-MSCs: pericytes
- Pericytes on capillaries in vivo
- MSCs in vivo are NOT multi-potent
- Pericytes of multiple organs do not behave as MSCs
- Cultured pericytes express markers of hMSCs
- The universal committed progenitor niche
- Medicinal signaling cell
- Committed progenitors
- Proposed sequence of change due to injury, 2023
- Natural injury response, 2023
- ClinicalTrials.gov search results
- 12 approved MSC therapies in the world (pre-2019 )
Topics Covered
- Mesenchymal Stem Cells (MSCs)
- Lineages and stem cells
- Embryonic chick limb bud mesenchymal cells
- Committed progenitors
- Tissue regeneration
- Adult bone marrow
- MSCs are not stem cells
- Pericytes
- Medicinal signaling cells
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Caplan, A.I. (2025, November 30). Bone marrow mesenchymal cells 1 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 6, 2025, from https://doi.org/10.69645/VYHW6301.Export Citation (RIS)
Publication History
- Published on November 30, 2025
Financial Disclosures
- Professor Caplan was the former Officer and Founder of Osiris Therapeutics, Inc which receives funding from Mesoblast Ltd. Royalties are shared between Case Western University and Prof. Caplan. Professor Caplan also provided a consulting service to many individuals and organisations globally within the regenerative medicine space.
Bone marrow mesenchymal cells 1
Published on November 30, 2025
36 min
A selection of talks on Immunology
Transcript
Please wait while the transcript is being prepared...
0:00
Hello there, my name
is Arnold Caplan.
I am a professor of biology at
Case Western Reserve University,
as it says on this slide.
I've been asked to talk about
bone marrow mesenchymal cells.
0:18
The next slide is my obligatory
disclosure information,
which is that I started a company
called Osiris Theapeutics,
and I have no association
with that company.
The university receives
royalties from Mesoblast,
which purchased the cell-based
therapy in 2013 from Osiris,
and they provide a royalty to
the Case Western
Reserve University,
which the university very
generously shares with me.
You can rest assured it's not
a big part of my
retirement package.
0:56
This is always a problem,
especially for those of
the people who are in
English-speaking countries.
There are two pronunciations
for the term mesenchyme or
mesenchymal or mesenchyme
or mesenchyme.
This is a very fancy word,
and it relates to the
middle layer of an embryo.
That layer of the
embryo gives rise to
all the connective tissue,
the bones, the cartilage,
and interestingly,
the blood supply.
From a very primitive
progenitor cell,
it differentiated into
your vasculature to
the cells associated
with your blood vessels,
to all of your blood cells,
and all of this
connective tissue.
In addition, the
mesenchyme talks to
other tissues in the embryo,
and it is actually involved in
almost every organ in the body.
I'll come back to that.
You'll see why
this is important.